BrYet Europe

Revolutionizing Cancer Therapy With Transport Oncophysics

Our Mission Is to Be the First to Develop Fully Curative Approaches to Metastatic Cancer.

We are focused on developing drugs for the prevention, treatment, and cure of metastatic cancers using nanoporous silicon microparticles.


Unprecedented Efficacy

Unprecedented efficacy in treating metastatic cancer has been demonstrated in preclinical trials.


Peer-reviewed Research

Our research has been published in leading peer-reviewed scientific journals.



Patent Protected

Protected by strong patent portfolio with technology licensed from Houston Methodist Research Institute & University of Texas Health Science Center at Houston.

About Us

BrYet Europe srl is the European branch of BrYet US Inc., a privately-owned biotech company focused on the discovery and development of novel physics-based, first-in-class therapies for metastatic liver and lung cancers.


Learn more about our research and technology.


Catch up on the latest news and more from BrYet.

Contact Us

Reach out for more information.


BrYet Europe S.r.l.

Via Roma, n.108,

Building CD1 20060

Cassina de’ Pecchi (Milan)